TABLE 3.
Summary of Biomarker Testing Procedures
| All Patients (N = 4,926) | Previously Diagnosed Patients (n = 1,186) | Newly Diagnosed Patients (n = 3,740) | |
|---|---|---|---|
| Overall population | |||
| Patients receiving biomarker testing, n | 675 | 80 | 595 |
| Before 2011 | 240 | 62 | 178 |
| After 2011 | 435 | 18 | 417 |
| Biomarker testing procedures, n | 741 | 87 | 654 |
| Before 2011 | 265 | 67 | 198 |
| After 2011 | 476 | 20 | 456 |
| Mean number of biomarker testing procedures per patient (SD) | 0.2 (0.4) | 0.1 (0.3) | 0.2 (0.4) |
| Before 2011 | 0.05 (0.3) | 0.06 (0.3) | 0.05 (0.3) |
| After 2011 | 0.10 (0.3) | 0.02 (0.1) | 0.12 (0.4) |
| Total biomarker testing procedures per patient, n (%) | |||
| 0 | 4,251 (86.3) | 1,150 (93.3) | 3,101 (84) |
| 1 | 614 (12.5) | 75 (6.1) | 539 (14.6) |
| 2 | 56 (1.1) | 7 (0.6) | 49 (1.3) |
| 3 | 5 (0.1) | 0 (0.0) | 5 (0.1) |
| Place of biomarker testing procedures, n (%) | |||
| Independent laboratory | 275 (37.1) | 26 (2.2) | 249 (6.7) |
| Outpatient | 266 (36) | 33 (2.8) | 233 (6.2) |
| Office/clinic | 174 (23.5) | 26 (2.2) | 148 (4.0) |
| Inpatient | 17 (2.3) | 2 (0.2) | 15 (0.4) |
| Emergency room | 2 (0.3) | 0 (0.0) | 2 (0.1) |
| Other | 7 (1.0) | 0 (0.0) | 7 (0.2) |
| Erlotinib recipients | |||
| Patients receiving biomarker testing procedures, n | 634 | 80 | 554 |
| By year, n (%) | |||
| 2009 | 71 (11.2) | 34 (2.8) | 38 (1.0) |
| 2010 | 168 (26.5) | 27 (2.3) | 141 (3.8) |
| 2011 | 226 (35.6) | 12 (1.0) | 214 (5.7) |
| 2012 | 169 (26.7) | 6 (0.5) | 163 (4.4) |
| Biomarker testing procedures, n | 698 | 87 | 611 |
| By year, n (%) | |||
| 2009 | 83 (11.9) | 36 (3.0) | 46 (1.2) |
| 2010 | 182 (26.1) | 30 (2.5) | 152 (4.1) |
| 2011 | 245 (35.1) | 13 (1.1) | 232 (6.2) |
| 2012 | 188 (26.9) | 7 (0.6) | 181 (4.8) |
| Mean number of biomarker testing procedures per patient (SD) | 0.2 (0.4) | 0.1 (0.3) | 0.2 (0.4) |
| Before 2011 | 0.06 (0.3) | 0.06 (0.3) | 0.05 (0.3) |
| After 2011 | 0.09 (0.3) | 0.02 (0.1) | 0.11 (0.6) |
| Total biomarker testing procedures per patient, n (%) | |||
| 0 | 4,167 (84.8) | 1,102 (92.9) | 3,065 (82.0) |
| 1 | 574 (12.0) | 73 (6.2) | 501 (13.4) |
| 2 | 56 (1.2) | 7 (0.6) | 49 (1.3) |
| 3 | 4 (0.1) | 0 (0.0) | 4 (0.1) |
| Crizotinib recipients | |||
| Patients receiving biomarker testing procedures, n | 41 | 0 | 41 |
| Biomarker testing procedure, n | 43 | 0 | 43 |
| Mean number of biomarker testing procedure per patient (SD) | 0.3 (0.5) | 0 (0.0) | 0.4 (0.5) |
| Total biomarker testing procedures per patient, n (%) | |||
| 0 | 84 (67.2) | 4 (100.0) | 80 (66.1) |
| 1 | 40 (32.0) | 0 (0.0) | 40 (33.1) |
| 2 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 3 | 1 (0.8) | 0 (0.0) | 1 (0.1) |
SD = standard deviation.